Amneal Pharmaceuticals, Inc. AMRX
Set alert
20.44 USD -1.07 -4.97%
At close
20.47 +0.03 +0.15%
Pre-market · Nov 3, 6:01 AM ET
20.30 Day range 21.68
10.68 52-week range 21.68
- YTD
- +62.22%
- 1 year
- +82.66%
- Open
- 21.53
- Prev close
- 21.51
- Mkt cap
- 7.12B
- Vol
- 5.02M
- Avg vol
- 2.84M
- EPS
- 0.49
- P/E
- 41.71
- Div yield
- 0.00%
More statistics
- Low
- 20.30
- High
- 21.68
- Forward P/E
- 16.94
- Beta
- 1.21
- Short ratio
- 3.80
- Inst. own
- 48.57%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 19.12
- 200-d avg
- 15.74
- 1y target
- 23.43
5Y chart
Events in this range
- Aug 5, 2025Earnings: 0.25; estimate 0.18; surprise 38.89%
- Oct 30, 2025Earnings: 0.17; estimate 0.13; surprise 30.77%
- Feb 27, 2026Earnings: 0.21; estimate 0.18; surprise 16.67%
- May 7, 2026Earnings: 0.27; estimate 0.17; surprise 58.82%
- Jul 15, 2026Rating: UBS · Buy → Buy
- Jul 30, 2026Earnings: 0.3; estimate 0.2225; surprise 34.83%
- Aug 3, 2026Rating: UBS · Buy → Buy
- Sep 9, 2026Rating: Leerink Partners · — → Outperform
- Sep 17, 2026Rating: Barclays · Overweight → Overweight
- Sep 23, 2026Rating: Oppenheimer · — → Outperform
- Oct 22, 2026Rating: JP Morgan · Overweight → Overweight
- Nov 3, 2026Earnings: —; estimate 0.2374; surprise —%
Signals (86)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| RSI: Overbought | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
Newest 20 of 86.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.43 +14.6% upside
Now 20.44
- Target (low)
- 20.00
- Target (mean)
- 23.43
- Target (high)
- 27.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.2374 | 0.202 – 0.28 | 0.17 | +39.7% | 817.86M | +4.3% | 7 |
| Next quarter | 0.22276 | 0.18 – 0.24 | 0.21 | +6.1% | 825.18M | +1.3% | 7 |
| Current year | 1.03 | 0.978 – 1.05 | 0.83 | +24.1% | 3.16B | +4.7% | 7 |
| Next year | 1.21 | 1.08 – 1.31 | 1.03 | +17.1% | 3.46B | +9.4% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 23, 2026 | Oppenheimer | Initiated | — | Outperform |
| Sep 17, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | Initiated | — | Outperform |
| Aug 3, 2026 | UBS | Maintained | Buy | Buy |
| Jul 15, 2026 | UBS | Maintained | Buy | Buy |
| May 20, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 17, 2026 | UBS | Initiated | — | Buy |
| Mar 2, 2026 | Truist Securities | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Oct 31, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 3, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Nov 11, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 2, 2024 | Truist Securities | Maintained | Buy | Buy |
| Sep 6, 2024 | JP Morgan | Upgrade | Underweight | Neutral |
| Aug 13, 2024 | Barclays | Maintained | Overweight | Overweight |
| Aug 12, 2024 | Truist Securities | Maintained | Buy | Buy |
| May 6, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| May 6, 2024 | Truist Securities | Reiterated | Buy | Buy |
| Mar 21, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 4, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 29, 2024 | Barclays | Maintained | Overweight | Overweight |
| Nov 8, 2023 | Truist Securities | Maintained | Buy | Buy |
| Sep 6, 2023 | Truist Securities | Reiterated | Buy | Buy |
| Aug 7, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 7, 2023 | Truist Securities | Maintained | Buy | Buy |
| Aug 7, 2023 | Barclays | Maintained | Overweight | Overweight |
| May 8, 2023 | Piper Sandler | Maintained | — | Overweight |